ICU Medical (NASDAQ:ICUI) Downgraded to Hold Rating by StockNews.com

ICU Medical (NASDAQ:ICUI - Get Free Report) was downgraded by investment analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Monday.

A number of other equities research analysts also recently weighed in on the company. Needham & Company LLC reissued a "hold" rating on shares of ICU Medical in a research report on Wednesday, November 13th. KeyCorp lifted their price objective on ICU Medical from $198.00 to $209.00 and gave the stock an "overweight" rating in a report on Wednesday, November 13th. Finally, Jefferies Financial Group raised ICU Medical from a "hold" rating to a "buy" rating and set a $200.00 target price for the company in a research report on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $168.67.

ICU Medical Stock Performance

ICU Medical stock traded down $1.40 during mid-day trading on Monday, reaching $140.19. The company had a trading volume of 191,815 shares, compared to its average volume of 234,440. The company has a 50 day moving average of $157.96 and a 200-day moving average of $165.25. ICU Medical has a 52 week low of $93.36 and a 52 week high of $196.26. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The firm has a market cap of $3.44 billion, a price-to-earnings ratio of -30.68 and a beta of 0.73.

Remove Ads

Insider Buying and Selling at ICU Medical

In other news, CEO Vivek Jain sold 1,373 shares of the firm's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $155.48, for a total transaction of $213,474.04. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company's stock, valued at approximately $16,262,119.64. This trade represents a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 6.70% of the company's stock.

Hedge Funds Weigh In On ICU Medical

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in ICU Medical by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 2,682,065 shares of the medical instruments supplier's stock valued at $416,176,000 after acquiring an additional 17,805 shares during the last quarter. State Street Corp lifted its position in ICU Medical by 9.3% during the 3rd quarter. State Street Corp now owns 907,607 shares of the medical instruments supplier's stock valued at $165,384,000 after purchasing an additional 77,506 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of ICU Medical by 7.4% in the 4th quarter. JPMorgan Chase & Co. now owns 708,382 shares of the medical instruments supplier's stock valued at $109,920,000 after purchasing an additional 49,108 shares during the last quarter. Geode Capital Management LLC grew its position in shares of ICU Medical by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier's stock worth $99,687,000 after buying an additional 48,106 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of ICU Medical by 18.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 539,981 shares of the medical instruments supplier's stock worth $83,788,000 after buying an additional 82,982 shares during the last quarter. 96.10% of the stock is owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.